Tumor Gene Testing

Make tumor medication more precise.

To provide patients with the most clear medication guidance for precision medicine, alleviate their pain, improve treatment accuracy, and reduce their economic burden.

There are differences in tumor driver gene mutations among different cancer patients. Through genetic testing, we can understand which genes have mutated in patients, which drugs are suitable, and which treatment methods are appropriate, achieving a "tailor-made" effect and achieving "precision medicine".

Neoantigen Discovery

Post-UMIPIC Neoantigen Discovery

Gene testing reaches its full potential when paired with UMIPIC therapy. The immunogenic cell death triggered by intratumoral injection releases a broad repertoire of tumor-specific neoantigens — genomic sequencing turns that biological window into an individualized treatment roadmap.

1
Sample Acquisition

Core needle biopsy 72–96 hours post-injection plus germline blood draw.

2
WES & RNA-Seq

Identify and confirm expression of somatic, non-synonymous mutations.

3
HLA Binding Prediction

Computational screening (NetMHCpan, MHCflurry) of candidate peptides.

4
Mass Spec Validation

Immunopeptidomics confirms in vivo presentation — the "gold standard."

5
T-Cell Reactivity Assays

ELISpot, ICS, and CD8⁺ cytotoxicity assays confirm functional immunogenicity.

Back to Technologies